Payment overview · 2025
General Payments
$198.44
10 reported records · 7 companies
Healthcare provider profile · identity verified
John A. E. Craig, M.D.
Allopathic & Osteopathic Physicians|Family Medicine · MINDEN, NE · NPI 1477999423
Verified facts
What the public records show
CMS Open Payments records show John A. E. Craig, M.D. received $198.44 in general payments during 2025 across 10 reported records.
Viatris Specialty LLC accounted for 25.3% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 12 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Ozempic, Rybelsus, Xifaxan.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 14 claims for Ozempic by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Rybelsus as an associated drug or biological on 161257 records involving 55409 distinct recipient NPIs. Public Medicare Part D data also shows 11 claims for Rybelsus by this doctor in 2024.
Salix Pharmaceuticals, a division of Bausch Health US, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported XIFAXAN as an associated drug or biological on 101901 records involving 33018 distinct recipient NPIs. Public Medicare Part D data also shows 25 claims for Xifaxan by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Viatris Specialty LLC | Unresolved — no canonical attribution shown | $50.26 | 25.3% | 2 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $41.01 | 20.7% | 2 | 2025 |
| Phathom Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $28.62 | 14.4% | 2 | 2025 |
| SCPHARMACEUTICALS INC. | Unresolved — no canonical attribution shown | $24.06 | 12.1% | 1 | 2025 |
| Merck Sharp & Dohme LLC | Unresolved — no canonical attribution shown | $19.71 | 9.9% | 1 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $19.43 | 9.8% | 1 | 2025 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | Unresolved — no canonical attribution shown | $15.35 | 7.7% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $198.44 | 10 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| YUPELRI Normalized: yupelri |
Drug | Viatris Specialty LLC | $50.26 | 2 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $41.01 | 2 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $41.01 | 2 | 2025 |
Source payment records
|
|||||
| VOQUEZNA Normalized: voquezna |
Drug | Phathom Pharmaceuticals, Inc. | $28.62 | 2 | 2025 |
Source payment records
|
|||||
| FUROSCIX Normalized: furoscix |
Drug | SCPHARMACEUTICALS INC. | $24.06 | 1 | 2025 |
Source payment records
|
|||||
| CAPVAXIVE Normalized: capvaxive |
Biological | Merck Sharp & Dohme LLC | $19.71 | 1 | 2025 |
Source payment records
|
|||||
| ENFLONSIA Normalized: enflonsia |
Drug | Merck Sharp & Dohme LLC | $19.71 | 1 | 2025 |
Source payment records
|
|||||
| GARDASIL 9 Normalized: gardasil 9 |
Biological | Merck Sharp & Dohme LLC | $19.71 | 1 | 2025 |
Source payment records
|
|||||
| ROTATEQ Normalized: rotateq |
Biological | Merck Sharp & Dohme LLC | $19.71 | 1 | 2025 |
Source payment records
|
|||||
| VAXNEUVANCE Normalized: vaxneuvance |
Biological | Merck Sharp & Dohme LLC | $19.71 | 1 | 2025 |
Source payment records
|
|||||
| EVENITY Normalized: evenity |
Biological | Amgen Inc. | $19.43 | 1 | 2025 |
Source payment records
|
|||||
| XIFAXAN Normalized: xifaxan |
Drug | Salix Pharmaceuticals, a division of Bausch Health US, LLC | $15.35 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| Ozempic ozempic |
2025 | Ozempic | 2024 | 14 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| Rybelsus rybelsus |
2025 | Rybelsus | 2024 | 11 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| XIFAXAN xifaxan |
2025 | Xifaxan | 2024 | 25 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
14 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Rybelsus open payments reported associated product |
CMS Open Payments — General Payments 161257 supporting records · 55409 recipient NPIs · example record 1188130076 |
Rybelsus · 2024 Exact normalized brand match · 1 Part D row |
11 | suppressed by CMS |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC Exact reporting entity; no affiliate inference |
2025 | XIFAXAN open payments reported associated product |
CMS Open Payments — General Payments 101901 supporting records · 33018 recipient NPIs · example record 1231775337 |
Xifaxan · 2024 Exact normalized brand match · 1 Part D row |
25 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 526 | 75 |
| Levothyroxine Sodium | Levothyroxine Sodium | 396 | 44 |
| Amlodipine Besylate | Amlodipine Besylate | 387 | 68 |
| Pantoprazole Sodium | Pantoprazole Sodium | 367 | 41 |
| Furosemide | Furosemide | 328 | 39 |
| Losartan Potassium | Losartan Potassium | 278 | 40 |
| Metoprolol Tartrate | Metoprolol Tartrate | 250 | 25 |
| Lisinopril | Lisinopril | 246 | 31 |
| Metoprolol Succinate | Metoprolol Succinate | 227 | 33 |
| Metformin Hcl | Metformin Hcl | 215 | 22 |
| Gabapentin | Gabapentin | 212 | 22 |
| Omeprazole | Omeprazole | 212 | 30 |
| Tamsulosin Hcl | Tamsulosin Hcl | 208 | 26 |
| Spironolactone | Spironolactone | 200 | 23 |
| Simvastatin | Simvastatin | 196 | 23 |
| Famotidine | Famotidine | 178 | 21 |
| Eliquis | Apixaban | 176 | 20 |
| Mirtazapine | Mirtazapine | 166 | 18 |
| Sertraline Hcl | Sertraline Hcl | 153 | 12 |
| Potassium Chloride | Potassium Chloride | 147 | 19 |
| Hydrochlorothiazide | Hydrochlorothiazide | 141 | 23 |
| Xarelto | Rivaroxaban | 136 | 14 |
| Allopurinol | Allopurinol | 133 | 16 |
| Duloxetine Hcl | Duloxetine Hcl | 122 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 116 | suppressed |
| Jardiance | Empagliflozin | 109 | suppressed |
| Escitalopram Oxalate | Escitalopram Oxalate | 101 | suppressed |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 96 | 16 |
| Carvedilol | Carvedilol | 82 | 13 |
| Zolpidem Tartrate | Zolpidem Tartrate | 81 | 11 |
| Pravastatin Sodium | Pravastatin Sodium | 78 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 75 | 11 |
| Clopidogrel | Clopidogrel Bisulfate | 70 | 12 |
| Pregabalin | Pregabalin | 68 | suppressed |
| Fluticasone Propionate | Fluticasone Propionate | 65 | 23 |
| Ezetimibe | Ezetimibe | 61 | suppressed |
| Oxycodone Hcl | Oxycodone Hcl | 60 | suppressed |
| Atenolol | Atenolol | 58 | suppressed |
| Tramadol Hcl | Tramadol Hcl | 58 | 12 |
| Amiodarone Hcl | Amiodarone Hcl | 57 | suppressed |
| Glimepiride | Glimepiride | 57 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 57 | suppressed |
| Alprazolam | Alprazolam | 56 | suppressed |
| Klor-Con M20 | Potassium Chloride | 55 | suppressed |
| Sucralfate | Sucralfate | 54 | suppressed |
| Midodrine Hcl | Midodrine Hcl | 53 | suppressed |
| Morphine Sulfate Er | Morphine Sulfate | 52 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 49 | suppressed |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 48 | suppressed |
| Chlorthalidone | Chlorthalidone | 45 | suppressed |
| Digoxin | Digoxin | 44 | suppressed |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 44 | suppressed |
| Glipizide Er | Glipizide | 43 | suppressed |
| Bumetanide | Bumetanide | 42 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 42 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 42 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 41 | suppressed |
| Lantus | Insulin Glargine,hum.Rec.Anlog | 40 | suppressed |
| Meloxicam | Meloxicam | 40 | suppressed |
| Enulose | Lactulose | 38 | suppressed |
| Metformin Hcl Er | Metformin Hcl | 38 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 36 | suppressed |
| Prednisone | Prednisone | 36 | 31 |
| Cefdinir | Cefdinir | 35 | 30 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 35 | suppressed |
| Nitrofurantoin | Nitrofurantoin Macrocrystal | 35 | suppressed |
| Spiriva Respimat | Tiotropium Bromide | 35 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 35 | 11 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 32 | 11 |
| Clonazepam | Clonazepam | 32 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 31 | suppressed |
| Lorazepam | Lorazepam | 31 | suppressed |
| Sotalol | Sotalol Hcl | 31 | suppressed |
| Myrbetriq | Mirabegron | 29 | suppressed |
| Tolterodine Tartrate Er | Tolterodine Tartrate | 29 | suppressed |
| Entresto | Sacubitril/Valsartan | 28 | suppressed |
| Levetiracetam | Levetiracetam | 28 | suppressed |
| Memantine Hcl | Memantine Hcl | 28 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 27 | 19 |
| Nebivolol Hcl | Nebivolol Hcl | 27 | suppressed |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 26 | suppressed |
| Toujeo Solostar | Insulin Glargine,hum.Rec.Anlog | 25 | suppressed |
| Xifaxan | Rifaximin | 25 | suppressed |
| Belsomra | Suvorexant | 24 | suppressed |
| Fentanyl | Fentanyl | 24 | suppressed |
| Zonisamide | Zonisamide | 24 | suppressed |
| Colestipol Hcl | Colestipol Hcl | 23 | suppressed |
| Humalog Kwikpen U-100 | Insulin Lispro | 23 | suppressed |
| Ranolazine Er | Ranolazine | 23 | suppressed |
| Trazodone Hcl | Trazodone Hcl | 23 | suppressed |
| Ultra-Fine Nano Pen Needle | Pen Needle, Diabetic | 23 | suppressed |
| Donepezil Hcl | Donepezil Hcl | 22 | suppressed |
| Kerendia | Finerenone | 22 | suppressed |
| Cephalexin | Cephalexin | 21 | suppressed |
| Risperidone | Risperidone | 21 | suppressed |
| Xtampza Er | Oxycodone Myristate | 21 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 20 | suppressed |
| Methylphenidate Hcl | Methylphenidate Hcl | 20 | suppressed |
| Mupirocin | Mupirocin | 20 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 20 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 20 | suppressed |
| Linzess | Linaclotide | 19 | suppressed |
| Insulin Lispro | Insulin Lispro | 18 | suppressed |
| Adacel Tdap | Diph,pertuss(Acell),tet Vac/Pf | 17 | 17 |
| Dilt-Xr | Diltiazem Hcl | 17 | suppressed |
| Propranolol Hcl Er | Propranolol Hcl | 17 | suppressed |
| Celecoxib | Celecoxib | 16 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 16 | suppressed |
| Propafenone Hcl | Propafenone Hcl | 16 | suppressed |
| Vascepa | Icosapent Ethyl | 16 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 15 | suppressed |
| Folic Acid | Folic Acid | 15 | suppressed |
| Montelukast Sodium | Montelukast Sodium | 15 | suppressed |
| Naproxen | Naproxen | 15 | suppressed |
| Arexvy | Rsvpref3 Antigen/As01e/Pf | 14 | 14 |
| Klor-Con 10 | Potassium Chloride | 14 | suppressed |
| Ondansetron Odt | Ondansetron | 14 | 11 |
| Ozempic | Semaglutide | 14 | suppressed |
| Victoza 2-Pak | Liraglutide | 14 | suppressed |
| Amantadine | Amantadine Hcl | 13 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 13 | 11 |
| Baclofen | Baclofen | 13 | suppressed |
| Finasteride | Finasteride | 13 | suppressed |
| Nystatin | Nystatin | 13 | suppressed |
| Shingrix | Varicella-Zoster Ge/As01b/Pf | 13 | 12 |
| Breo Ellipta | Fluticasone/Vilanterol | 12 | suppressed |
| Brilinta | Ticagrelor | 12 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 12 | suppressed |
| Desvenlafaxine Succinate Er | Desvenlafaxine Succinate | 12 | suppressed |
| Diazepam | Diazepam | 12 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 12 | suppressed |
| Flecainide Acetate | Flecainide Acetate | 12 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 12 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 12 | suppressed |
| Metolazone | Metolazone | 12 | suppressed |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 12 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 12 | suppressed |
| Topiramate | Topiramate | 12 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 12 | suppressed |
| Aripiprazole | Aripiprazole | 11 | suppressed |
| Diltiazem Hcl | Diltiazem Hcl | 11 | suppressed |
| Humalog Mix 75-25 Kwikpen | Insulin Lispro Protamin/Lispro | 11 | suppressed |
| Incruse Ellipta | Umeclidinium Bromide | 11 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 11 | suppressed |
| Morphine Sulfate | Morphine Sulfate | 11 | suppressed |
| Rybelsus | Semaglutide | 11 | suppressed |
| Tizanidine Hcl | Tizanidine Hcl | 11 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 11 | suppressed |
| Ulticare Pen Needle | Pen Needle, Diabetic | 11 | suppressed |
| Verapamil Hcl | Verapamil Hcl | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $198.44 · 10 records | Viatris Specialty LLC | CAPVAXIVE, ENFLONSIA, EVENITY, FUROSCIX, GARDASIL 9, Ozempic, ROTATEQ, Rybelsus, VAXNEUVANCE, VOQUEZNA, XIFAXAN, YUPELRI | 3 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Ozempic play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with Novo Nordisk Inc?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error